家族性地中海热中的秋水仙碱抵抗与不耐受:定义、原因及替代治疗
家族性地中海热(FMF)以反复浆膜炎或关节炎发作为特征,秋水仙碱是金标准治疗,可减少发作频率和淀粉样变性风险。但高达5%的患者被认为对秋水仙碱抵抗或反应不足,另有一些患者无法耐受有效剂量的副作用。评估抵抗需考虑发作频率与严重程度、急性期反应物水平、秋水仙碱剂量与成分及治疗依从性;靶向白细胞介素-1的生物制剂在抵抗或不耐受患者中已获有前景的临床结果。
要点
- 秋水仙碱是FMF金标准治疗,可降低发作频率和淀粉样变性风险。
- 高达5%的FMF患者对秋水仙碱抵抗或反应不足。
- 评估抵抗需综合发作频率与严重程度、急性期反应物、剂量与成分及依从性。
核心结论
- 需识别秋水仙碱治疗未达最优的患者,这些患者可能从附加生物制剂治疗中获益。
研究设计与样本
- 综述性文章,探讨秋水仙碱抵抗定义演变及可能解释无反应的秋水仙碱相关特征。
主要发现
- 高达5%的FMF患者被认为对秋水仙碱抵抗或反应不足。
- 部分患者无法耐受有效剂量秋水仙碱的副作用。
- 靶向白细胞介素-1的生物制剂在秋水仙碱抵抗或不耐受的FMF患者中已获有前景的临床结果。
关键数值与推荐
- 评估秋水仙碱抵抗的关键因素包括发作频率与严重程度、急性期反应物水平、秋水仙碱剂量与成分及治疗依从性。
临床怎么用
- 对秋水仙碱治疗未达最优的FMF患者,应考虑评估抵抗或不耐受并考虑附加白细胞介素-1靶向生物制剂。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Familial Mediterranean Fever (FMF) is a hereditary autoinflammatory syndrome characterized by recurrent serositis or arthritis attacks and, in some patients, chronic subclinical inflammation that predisposes to secondary amyloidosis. Colchicine is the gold standard of treatment, which reduces attack frequency and amyloidosis risk. However, up to 5% of patients are considered resistant or inadequately respond to colchicine, and some others cannot tolerate the side effects of effective doses of colchicine (colchicine intolerant). METHODS: We examine how the definition of colchicine resistance has evolved along with various characteristics of colchicine that may help explain unresponsiveness to the drug. RESULTS: Key factors in assessing colchicine resistance include attack frequency and severity, levels of acute phase reactants, colchicine dosage and composition, and treatment compliance. Promising clinical results have been obtained with biologics targeting interleukin-1 in colchicine-resistant or -intolerant patients with FMF. CONCLUSIONS: These results underscore the need to identify patients who are not optimally managed with colchicine and who might therefore benefit from additional biologic therapies.
引用
- Ozen S, Kone-Paut I, Gül A, et al. Colchicine resistance and intolerance in familial mediterranean fever: Definition, causes, and alternative treatments. Semin Arthritis Rheum. 2017. PMID: 28413100. doi:10.1016/j.semarthrit.2017.03.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。